TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21523459

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (A) - physiotherapist guided stretching and strengthening exercises, 12 sessions over 12 weeks, with home exercises up to 24 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard postoperative treatment group (B) - normal postoperative treatment or no treatment/self-management
Number of subjects: 102
Study: 18295613

Group type: EXPERIMENTAL
Intervention: Mirror therapy (30 minutes a day, 5 days a week for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham therapy (control group)
Number of subjects: 40
Study: 16805357

Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)2) apexification (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) apexification (experimental)
Number of subjects: 15
Study: 14594886

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg orally for 12 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (30 normal participants)
Number of subjects: 30
Study: 11079645

Group type: EXPERIMENTAL
Intervention: Short-term vitamin C therapy (intravenous)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Long-term vitamin C therapy (oral)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 8869533

Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 0

Group type: COMPARATOR
Intervention: Survanta
Number of subjects: 0
Study: 1740597

Group type: EXPERIMENTAL
Intervention: Patterned urge-response toileting (PURT) intervention over 12 weeks.
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Volume of UI among the experimental group.
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 113
Study: 6603496

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transcutaneous (placebo) stimulation
Number of subjects: 10
Study: 31846631

Group type: EXPERIMENTAL
Intervention: 12-week daily meal with fresh Hass avocado
Number of subjects: 84

Group type: COMPARATOR
Intervention: Isocaloric meal (control group)
Number of subjects: 84
Study: 31079203

Group type: EXPERIMENTAL
Intervention: Lens extraction (LE, phacoemulsification with posterior chamber intraocular lens implantation)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 122
Study: 28924368

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anesthesia with postoperative ketorolac analgesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil anesthesia with postoperative fentanyl analgesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane-fentanyl group
Number of subjects: 50
Study: 26869944

Group type: EXPERIMENTAL
Intervention: Home-based auditory training (13 sessions over 4 weeks)
Number of subjects: 56
Study: 23812612

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser and acoustic pressure ultrasound for transepidermal delivery of cosmeceuticals
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fractional CO2 laser alone
Number of subjects: 14
Study: 21528595

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pinaverium Bromide (50 mg, 3 times a day for 30 days)
Number of subjects: 60
Study: 19366490

Group type: EXPERIMENTAL
Intervention: 30 mg/kg x d DSR
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16673738

Group type: EXPERIMENTAL
Intervention: Night vision goggles (NVGs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambient light
Number of subjects: 0
Study: 15293131

Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-urea breath test
Number of subjects: 255
Study: 11535445

Group type: EXPERIMENTAL
Intervention: 20 Gy of external beam therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 42
Study: 8295092

Group type: EXPERIMENTAL
Intervention: 0.15% chlorhexidine digluconate solution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium benzoate-sodium bicarbonate (SBSB) compound
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 18
Study: 3471181

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Peritonitis
Number of subjects: 145
Study: 29789518

Group type: EXPERIMENTAL
Intervention: Clinoleic (olive oil based)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Intralipid (soybean oil based)
Number of subjects: 206
Study: 26714981

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (808 nm, 250 J/cm², 100 mW, 7 J each point)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo laser session
Number of subjects: 30
Study: 25427845

Group type: EXPERIMENTAL
Intervention: Random (non‐fasting) blood glucose testing (RBGT)
Number of subjects: 5483

Group type: EXPERIMENTAL
Intervention: Australian type 2 diabetes risk assessment tool (AUSDRISK)
Number of subjects: 5483

Group type: EXPERIMENTAL
Intervention: Both RBGT and AUSDRISK
Number of subjects: 5483

Group type: COMPARATOR
Intervention: AUSDRISK
Number of subjects: 5483
Study: 23566722

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonbuffered lidocaine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (after adjustment)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonbuffered lidocaine (after adjustment)
Number of subjects: 25
Study: 20651059

Group type: EXPERIMENTAL
Intervention: sorafenib 400 mg twice a day
Number of subjects: 903

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 903
Study: 18982206

Group type: EXPERIMENTAL
Intervention: APAP with heated humidification
Number of subjects: 39

Group type: COMPARATOR
Intervention: APAP without heated humidification
Number of subjects: 39
Study: 16819595

Group type: EXPERIMENTAL
Intervention: Multimedia touch screen system (MTS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Translated patient information leaflet (PIL) plus verbal support
Number of subjects: 69

Group type: COMPARATOR
Intervention: Fluent English speakers (FE)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Overall inhaler technique
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Inhaler shaking and mouthpiece checking
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Co-ordination of inspiration and inhaler actuation
Number of subjects: 69
Study: 14506483

Group type: EXPERIMENTAL
Intervention: 20 g low-fat (40%) spread fortified with 200 microg FA and a placebo tablet
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 20 g low-fat placebo spread and a 200 microg FA tablet
Number of subjects: 13

Group type: COMPARATOR
Intervention: 20 g low-fat placebo spread and a placebo tablet
Number of subjects: 13
Study: 10392865

Group type: EXPERIMENTAL
Intervention: High-dose recombinant urokinase (350,000 IU/hour for 6 hours, then 125,000 IU/hour for up to 18 hours)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Low-dose recombinant urokinase (125,000 IU/hour for 6 hours, then 125,000 IU/hour for up to 18 hours)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: High-dose recombinant urokinase
Number of subjects: 107

Group type: COMPARATOR
Intervention: Low-dose recombinant urokinase
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both doses of recombinant urokinase
Number of subjects: 107
Study: 9373124

Group type: EXPERIMENTAL
Intervention: Ofloxacin (0.3%)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional dual therapy (gentamicin 1.5% and cefuroxime 5.0%)
Number of subjects: 122
Study: 8253492

Group type: EXPERIMENTAL
Intervention: BR-16A (Mentat)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 4020517

Group type: EXPERIMENTAL
Intervention: Random scaling of the display; addition of flanking bars at varying distances
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flanking bars too close (less than about 2 arc min) or optically blurred display
Number of subjects: 0
Study: 31492775

Group type: EXPERIMENTAL
Intervention: Strength training intervention for hypogonadal patients with testosterone replacement therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Strength training intervention for newly diagnosed males without testosterone replacement therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Strength training intervention for age-matched healthy eugonadal males
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (hypogonadal patients without strength training)
Number of subjects: 66
Study: 29980005

Group type: EXPERIMENTAL
Intervention: Single‐shot ultrasound (US)‐guided ESP block with 20 ml 0.25% bupivacaine at the T4 vertebral level
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups provided with intravenous patient‐controlled analgesia device containing morphine
Number of subjects: 50
Study: 27809882

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 62
Study: 25364676

Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen 1 (evening dose at 06.00-07.00 pm)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hydrocortisone regimen 2 (evening dose at 09.00-10.00 pm)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prednisolone regimen (evening dose at 10.00 pm)
Number of subjects: 13
Study: 22931628

Group type: EXPERIMENTAL
Intervention: Indwelling urinary catheters removed at 6-8 hours after cesarean section
Number of subjects: 138

Group type: COMPARATOR
Intervention: Indwelling urinary catheters removed at 24 hours after cesarean section
Number of subjects: 138
Study: 20565156

Group type: EXPERIMENTAL
Intervention: Preventive intervention for divorced families
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Program for mothers only
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Program participation
Number of subjects: 240
Study: 18705533

Group type: EXPERIMENTAL
Intervention: Telmisartan monotherapy (10-160 mg)
Number of subjects: 16416

Group type: EXPERIMENTAL
Intervention: Telmisartan plus HCTZ (10-160 mg + 6.25-25 mg)
Number of subjects: 16416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16416

Group type: EXPERIMENTAL
Intervention: Telmisartan monotherapy (open-label)
Number of subjects: 16416

Group type: EXPERIMENTAL
Intervention: Telmisartan plus HCTZ (open-label)
Number of subjects: 16416

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 16416
Study: 15983428

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 12947329

Group type: EXPERIMENTAL
Intervention: Sample size calculations reported in RCTs
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Studies with positive treatment effect
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Studies appropriately powered to detect a 50% effect change
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Studies with power to detect a 20% difference
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Underpowered studies needing increased sample size
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Overall reporting of sample size calculations
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Studies with appropriate sample sizes
Number of subjects: 127
Study: 10593790

Group type: EXPERIMENTAL
Intervention: Hypoxic gas inhalation with aerosolized methacholine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxic gas inhalation with aerosolized methacholine
Number of subjects: 12
Study: 8722544

Group type: EXPERIMENTAL
Intervention: Erythromycin (1 g)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Clindamycin (0.6 g)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Erythromycin and Clindamycin
Number of subjects: 38
Study: 1358932

Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms vs Salbutamol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms vs Salbutamol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms vs Salmeterol 25 micrograms
Number of subjects: 20
Study: 6097818

Group type: EXPERIMENTAL
Intervention: Gyno‐Travogen® vaginal tablets (300 mg isoconazole nitrate each)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nizoral® tablets (200 mg ketoconazole each)
Number of subjects: 140
Study: 30251736

Group type: EXPERIMENTAL
Intervention: Er: YAG laser etched enamel (1.5W, 15Hz)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acid etched enamel (37% phosphoric acid for 30 seconds)
Number of subjects: 50
Study: 27900987

Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/micronized progesterone (MP) 100 mg daily (Group A)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/MP 100 mg daily (Group B)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/dydrogesterone 10 mg daily (Group C)
Number of subjects: 123
Study: 25248815

Group type: EXPERIMENTAL
Intervention: CRP levels >3 mg/L
Number of subjects: 581

Group type: COMPARATOR
Intervention: CRP levels <1 mg/L
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Baseline CRP levels
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: 1-year MACE
Number of subjects: 581
Study: 22763155

Group type: EXPERIMENTAL
Intervention: 800 IU of vitamin D2 (drops)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 800 IU of vitamin D3 (pills)
Number of subjects: 21
Study: 20619140

Group type: EXPERIMENTAL
Intervention: Acupuncture applied to Zusanli and other acupoints, once a day.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Metoclopramide, 20 mg intramuscularly injected three times a day.
Number of subjects: 63
Study: 17562523

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 81
Study: 16191351

Group type: EXPERIMENTAL
Intervention: 5.0% phenylephrine hydrochloride
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mydrin-P
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0.3% Tarivid
Number of subjects: 19
Study: 11806983

Group type: EXPERIMENTAL
Intervention: 2 delayed-intensification phases (DDI)
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Single delayed-intensification (DI)
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Single delayed-intensification with increased vincristine and prednisone pulses (DIVPI)
Number of subjects: 1204
Study: 10063824

Group type: COMPARATOR
Intervention: 50% intensity group
Number of subjects: 27

Group type: COMPARATOR
Intervention: 70% intensity group
Number of subjects: 27
Study: 7577891

Group type: EXPERIMENTAL
Intervention: Amylase-treated maize-based weaning food
Number of subjects: 10

Group type: COMPARATOR
Intervention: Maize-based weaning food (before amylase treatment)
Number of subjects: 10
Study: 2202770

Group type: EXPERIMENTAL
Intervention: OK-432 (5KE X 1/W)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: OK-432 (5KE X 3/W)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: OK-432 (20KE X 3/W)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: OK-432 (all groups)
Number of subjects: 88
Study: 6284566

Group type: EXPERIMENTAL
Intervention: Wheat bran diet
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no diet supplementation)
Number of subjects: 38
Study: 30760125

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1315
Study: 30171280

Group type: EXPERIMENTAL
Intervention: Cyclosporine 200 mg + Eltrombopag 50 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cyclosporine 600 mg + Eltrombopag 50 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Eltrombopag 50 mg alone
Number of subjects: 39
Study: 26988949

Group type: EXPERIMENTAL
Intervention: Aspirin plus prasugrel
Number of subjects: 9294

Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel
Number of subjects: 9294
Study: 23777441

Group type: EXPERIMENTAL
Intervention: Single 2.5 mg/0.1 mL dose of subconjunctival bevacizumab immediately after surgery (group 1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Double 2.5 mg/0.1 mL injection of subconjunctival bevacizumab (one immediately after surgery and the second 15 days after surgery) (group 2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No injection (group 3)
Number of subjects: 49
Study: 22809589

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 138
Study: 20823783

Group type: EXPERIMENTAL
Intervention: Lumbar support plus usual care
Number of subjects: 360
Study: 17100978

Group type: EXPERIMENTAL
Intervention: Transparent hood
Number of subjects: 684

Group type: COMPARATOR
Intervention: Short hood
Number of subjects: 684

Group type: COMPARATOR
Intervention: No hood
Number of subjects: 684
Study: 16376769

Group type: EXPERIMENTAL
Intervention: Left atrial volume index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitral E/e' ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise capacity (percentage of predicted peak VO2)
Number of subjects: 0
Study: 12197843

Group type: EXPERIMENTAL
Intervention: Simethicone (105 mg t.d.s.)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg t.d.s.)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (t.d.s.)
Number of subjects: 185
Study: 9462386

Group type: EXPERIMENTAL
Intervention: Epoetin beta 20,000 units/day subcutaneously for at least 10 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 102
Study: 8534649

Group type: EXPERIMENTAL
Intervention: Intracapsular cataract extraction with IOL (343 patients)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Intracapsular cataract extraction without IOL (319 patients)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Total study population (662 patients)
Number of subjects: 662
Study: 2650602

Group type: EXPERIMENTAL
Intervention: Fat stitches
Number of subjects: 22

Group type: COMPARATOR
Intervention: No fat stitches (implied control)
Number of subjects: 22
Study: 648077

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metaproterenol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31136474

Group type: EXPERIMENTAL
Intervention: Digital image speckle correlation analysis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physician assessment based on 2004 facial aesthetics consensus recommendations
Number of subjects: 10
Study: 28455675

Group type: EXPERIMENTAL
Intervention: Larger disc diameters (greater than 6 mm)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Disc diameter cutoffs (5, 6, 7, or 8 mm)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Disc volume removed
Number of subjects: 63
Study: 26465985

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU)
Number of subjects: 2259

Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg)
Number of subjects: 2259

Group type: EXPERIMENTAL
Intervention: Both vitamin D3 (1000 IU) and calcium (1200 mg)
Number of subjects: 2259

Group type: COMPARATOR
Intervention: Placebo (neither agent)
Number of subjects: 2259
Study: 23602247

Group type: EXPERIMENTAL
Intervention: Bison (12 oz serving)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Beef (12 oz serving)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Beef (7 weeks chronic consumption)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bison (7 weeks chronic consumption)
Number of subjects: 24
Study: 20689455

Group type: EXPERIMENTAL
Intervention: Fruit, berry, and vegetable concentrate (FVC), Juice Plus+® (NSA LLC, Collierville, TN), supplement
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 41
Study: 19626400

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times per day)
Number of subjects: 87
Study: 16422738

Group type: EXPERIMENTAL
Intervention: Structured reminiscence group sessions held twice weekly for a six-week period
Number of subjects: 24

Group type: COMPARATOR
Intervention: Activity (control) group
Number of subjects: 24
Study: 15239968

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation for 20 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic hypoxia in rats
Number of subjects: 0
Study: 11700812

Group type: EXPERIMENTAL
Intervention: Vitamin C 1 g
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Vitamin C 3 g
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Vitamin C 3 g with additives ('Bio-C')
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (0.03 g vitamin C)
Number of subjects: 400
Study: 9424970

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (small doses)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination of intraarticular morphine and bupivacaine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intraarticular drainage and patient-controlled analgesia
Number of subjects: 34

Group type: COMPARATOR
Intervention: Adrenaline addition, tourniquet use, time interval between injection and tourniquet release
Number of subjects: 34
Study: 7962426

Group type: EXPERIMENTAL
Intervention: Immunotherapy with 200 x 10(6) purified paternal lymphocytes before pregnancy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 44